CibusCBUS
CBUS
About: Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
Employees: 183
0
Funds holding %
of 7,139 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
250% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 8
157% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 7
14% more funds holding
Funds holding: 57 [Q3] → 65 (+8) [Q4]
1.55% more ownership
Funds ownership: 34.16% [Q3] → 35.72% (+1.55%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
10% less capital invested
Capital invested by funds: $29.2M [Q3] → $26.3M (-$2.9M) [Q4]
68% less call options, than puts
Call options by funds: $13K | Put options by funds: $40K
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$18
765%
upside
Avg. target
$18
765%
upside
High target
$18
765%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Canaccord Genuity Austin Moeller 33% 1-year accuracy 16 / 49 met price target | 765%upside $18 | Buy Maintained | 22 Jan 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
Cibus Announces Important Update to Rice Gene Editing Conversion Rates
SAN DIEGO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today issued a correction relating to the rice conversion rates previously disclosed in its January 16, 2025 press release. The Company has concluded that the gene editing conversion rates of 10-25% in Rice have not been reconfirmed based upon subsequent experiments and high variability in the conversion rate data.
Neutral
GlobeNewsWire
1 month ago
Cibus to Participate in the Sidoti Micro Cap Conference
SAN DIEGO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company”), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that Rory Riggs, Co-Founder, Chief Executive Officer, and Chairman, and Peter Beetham, Co-Founder, President, and Chief Operating Officer, will host a presentation at the Sidoti Micro Cap Conference.
Neutral
GlobeNewsWire
1 month ago
Cibus, Inc. Announces $22.6 Million Registered Direct Offering Priced Above Nasdaq's Minimum Price in Accordance with Nasdaq Rules
SAN DIEGO, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced it has entered into securities purchase agreements with existing investors of the Company, including institutional and strategic investors, as well as with the Company's CEO, Rory Riggs, for the purchase and sale of 9,040,000 shares of its Class A Common Stock (inclusive of pre-funded warrants to purchase shares of Class A Common Stock, in lieu of common stock), and warrants to purchase up to an aggregate of 9,040,000 shares of Class A Common Stock, at a combined purchase price per share (and accompanying warrant) of $2.50 per share ($2.4999 in respect of the pre-funded warrants (and accompanying warrant)), pursuant to a registered direct offering priced above Nasdaq's Minimum Price in accordance with Nasdaq rules. The warrants will be exercisable upon stockholder approval at a price of $2.50 per share, and will expire five years following the date of stockholder approval. Following stockholder approval, the warrants will be redeemable, at the Company's option, at a redemption price of $0.0001 per warrant following the satisfaction of certain conditions, including (i) the Company's announcement of an operational soybean platform and (ii) the closing price of the Class A Common Stock equaling or exceeding $5.00 per share for fifteen consecutive trading days.
Neutral
GlobeNewsWire
2 months ago
Cibus, Albaugh LLC and RTDC Company Limited Affirm Collaboration to Enable Commercialization of Cibus' First Gene Edited Weed Management Solution for U.S. Rice Growers
Cibus' Rice Herbicide Tolerance (HT-3) Commercialization Efforts Continue Promising Progress to deliver a new Weed Management Solution for Farmers in the U.S.
Neutral
GlobeNewsWire
3 months ago
Cibus and Biographica Announce Collaboration Using Artificial Intelligence (AI) to Advance Disease Resistance in Canola and Oilseed Rape
Cibus and Biographica to collaborate on identifying gene editing targets for Cibus' disease resistance trait development
Neutral
GlobeNewsWire
3 months ago
Cibus to Participate in the 13th Annual Roth Technology Conference
SAN DIEGO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company”), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced that Rory Riggs, Co-Founder, Chief Executive Officer, and Chairman, will participate in the 13th Annual Roth Technology Conference.
Neutral
Seeking Alpha
3 months ago
Cibus, Inc. (CBUS) Q3 2024 Earnings Call Transcript
Cibus, Inc. (NASDAQ:CBUS ) Q3 2024 Results Conference Call November 7, 2024 4:30 PM ET Company Participants Carlo Broos - Chief Financial Officer Rory Riggs - Co-Founder, Chairman and CEO Peter Beetham - Co-Founder, President and COO Conference Call Participants Laurence Alexander - Jefferies Austin Moeller - Canaccord Matthew Venezia - Alliance Global Partners Operator Good day, and welcome to the Cibus Third Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode.
Positive
Zacks Investment Research
3 months ago
Cibus (CBUS) Q3 Earnings and Revenues Top Estimates
Cibus (CBUS) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.90 per share. This compares to loss of $1.59 per share a year ago.
Neutral
GlobeNewsWire
3 months ago
Cibus Reports Third Quarter Financial Results and Provides Year-to-Date Business Update for 2024
Announced a strategic realignment to advance commercial opportunities, focusing resources on advancement of weed management platform (HT1 and HT3) for Rice, Pod Shatter Reduction in Canola, Sclerotinia resistance for Canola and Soybean, and on Soybean platform development
Neutral
GlobeNewsWire
3 months ago
Cibus Confirms its Herbicide Tolerance (HT2) Trait Shows Increased Tolerance to a Novel Herbicide for Weed Control in Canola
The greenhouse results represent an important success milestone in the development of its second-generation of HT2 edited Canola
Charts implemented using Lightweight Charts™